Be Ready to Dispense Paxlovid or Molnupiravir for COVID-19
February 2022
You'll start to see Rxs for two new oral antivirals to treat COVID-19, Paxlovid (nirmatrelvir/ritonavir) or molnupiravir.
Either is an option for patients with mild to moderate COVID-19 who are at high risk of developing serious illness (age 65 or older, diabetes, etc)...regardless of vaccination status.
Be ready to handle these Rxs correctly...and ensure safe use.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote